- Home
- ZUMZ vs PROK Comparison
ZUMZ vs PROK Comparison
Compare ZUMZ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZUMZ | PROK |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 417.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZUMZ | PROK |
|---|---|---|
| Price | $29.42 | $2.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $6.25 |
| AVG Volume (30 Days) | 302.8K | ★ 1.2M |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $916,909,000.00 | $744,000.00 |
| Revenue This Year | $5.50 | $918.66 |
| Revenue Next Year | $1.36 | N/A |
| P/E Ratio | $58.96 | ★ N/A |
| Revenue Growth | ★ 2.81 | N/A |
| 52 Week Low | $11.31 | $0.46 |
| 52 Week High | $31.70 | $7.13 |
Technical Indicators
Market Signals| Indicator | ZUMZ | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 39.24 |
| Support Level | $28.55 | $2.09 |
| Resistance Level | $31.70 | $2.29 |
| Average True Range (ATR) | 1.24 | 0.17 |
| MACD | 0.17 | 0.01 |
| Stochastic Oscillator | 71.51 | 13.11 |
Price Performance
Historical ComparisonAbout ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.